Table 3 Changes in TB incidence rate during antiretroviral therapy among 583 patients initiating treatment.
From: The tuberculosis challenge in a rural South African HIV programme
Initial 3 months (n = 583 individuals) | After 3 months (n = 559 individuals) | |||
|---|---|---|---|---|
Variable | Unadjusted Hazard Ratio (95% CI) | Adjusted Hazard Ratio (95% CI) | Unadjusted Hazard Ratio (95% CI) | Adjusted Hazard Ratio (95% CI) |
Age (years) | 0.99 (0.95-1.04) | 0.87 (0.79-0.96) | 0.98 (0.95-1.10) | N/S |
Sex; | ||||
Female | REF | REF | ||
Male | 4.17 (1.83-.54) | 9.55 (2.35-38.78) | 0.59 (0.30-1.16) | 0.55 (0.27-1.10) |
Log 10 HIV RNA | 1.85 (0.86-3.97) | 2.69 (1.11-6.51) | 0.83 (0.59-1.13) | N/S |
Transfer in | 0.99 (0.13-7.30) | N/S | 0.38 (0.05-2.78) | N/S |
Log 10 CD4 | 1.35 (0.78-2.40) | 2.02 (0.58-4.76) | 0.83 (0.65-1.07) | 0.87(0.67-1.13) |
Prior TB; | ||||
No | REF | REF | ||
Yes | 1.42 (0.63-3.20) | 1.16 (0.33-4.03) | 1.77 (1.04-2.98) | 1.32 (0.73-2.38) |
WHO stage | ||||
1 or 2 | REF | REF | ||
3 or 4 | 2.33 (0.92-5.92) | N/S | 2.11 (1.15-3.87) | 1.94 (0.99-3.38) |
Unknown | 0.40 (0.05-3.32) | N/S | 1.27 (0.52-3.12) | 1.43 (0.58-3.56) |